Mcmillan’s profit declined in fiscal 2018

Mc Millan

Mcmillan Shakespeare’s net profit after tax fell 25.9% for the year ending 30 June 2018 but revenue from continuing operations rose 4.2%. Net profit from ordinary activities after income tax was $50.30 million including one-off payments in relation to transaction costs incurred in acquisitions. Subsequently, underlying NPAT was up 7.2% to $93.5 million.

There has been geographic expansion and UNPATA growth of 42.5% in the UK business which is mainly attributable to acquisitions made in the UK over the last 12 months. Australia and New Zealand has shown UNPATA growth of 17% driven by enhanced funding model and cost management. UNPATA was up 7.2% to $93.5 million in financial year ending 30 June 2018.

Carbon neutral certified, MMS has reported continued growth in customers and assets, which includes 18.7% growth in net amount financed of $2.8 billion in FY18. The units of assets managed increased to 42,750, up 2.3%, in fiscal 2018.

Underlying earnings per share continued to move on upwards trend as it increased by 8% to 113.2 cents in FY18. Earnings before interest tax, depreciation and amortization grew 4.4% to 143.4 million from 137.3 million in previous year.

The annual yield declared during the year was 73 cents including fully franked final dividend of 40 cents payable on 28 September 2018 with record date of 14 September 2018. This represents 10.6% of hike in total dividend as compared to previous year’s yield. Capital and operational cost is expected to increase in FY19.

MMS share price sinked 3.932% to $15.150 on Wednesday 22 August 2018.

Sponsored ad by Kalkine

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report

LEAVE A REPLY

Please enter your comment!
Please enter your name here